Back to Newsroom

Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia

CAMBRIDGE, Mass., Dec. 5, 2013 – Catabasis Pharmaceuticals, Inc., today announced the initiation of a Phase 2 clinical trial investigating the safety and efficacy of CAT-2003 in patients with severe hypertriglyceridemia, defined as serum triglyceride levels of 500 mg/dL or greater. CAT-2003 is a conjugate of niacin and the omega 3 fatty acid, eicosapentaenoic acid (EPA), employing Catabasis’ proprietary SMART Linker technology.